We present a rare case of primary chondrosarcoma of the liver in a 57-year-old man with pre-existing hepatitis B virus-related chronic hepatitis.The MRI scans showed a huge cystic-solid occupation of 18 cm×17 cm&...We present a rare case of primary chondrosarcoma of the liver in a 57-year-old man with pre-existing hepatitis B virus-related chronic hepatitis.The MRI scans showed a huge cystic-solid occupation of 18 cm×17 cm×11 cm in the right hepatic lobe.The tumor was completely resected,and the histological findings identified low-grade cartilaginous component with typical ring-and-arc chondroid matrix mineralization.Immunohistochemically,the neoplastic cells were positive for vimentin and S-100 protein.The patient received once postoperative adjuvant transcatheter arterial chemoembolization(TACE)at the 2nd month after discharge,and he is still alive for more than 13 months without recurrence and metastasis.To the best of our knowledge,this is the first case of primary chondrosarcoma of the liver.展开更多
Summary Existence of a graft-versus-myeloma effect has been well documented by responses to donor lymphocyte infusions and long-term survival after allogeneic bone marrow transplantation. The development of non-myeloa...Summary Existence of a graft-versus-myeloma effect has been well documented by responses to donor lymphocyte infusions and long-term survival after allogeneic bone marrow transplantation. The development of non-myeloablative conditioning regimens allows utilization of allogeneic effects in patients usually not suitable for myeloablative allogeneic transplantation, such as older and heavily pretreated patients. In a small series of 11 patients with multiple myeloma relapsing after autologous transplantation, we show that conditioning with low-dose total body irradiation in combination with fludarabine allows stable engraftment after matched unrelated donor transplantation and is tolerated with acceptable transplant-related morbidity and mortality. With a short median follow-up of 225 days, disease control was achieved only for patients responding to conventional treatment prior to allografting. Future studies with longer follow-up have to define the role of non-myeloablative allogeneic transplantation from unrelated donors as consolidation for patients responding to salvage therapy.展开更多
Knee Osteoarthritis, a retrograde disease, is mainly characterized by pain in the knee joints and limitation of the movement. It is a common and frequently occurring disease affecting the health and life quality of ol...Knee Osteoarthritis, a retrograde disease, is mainly characterized by pain in the knee joints and limitation of the movement. It is a common and frequently occurring disease affecting the health and life quality of old people. In recent years, acupuncture treatment of knee osteoarthritis with satisfactory therapeutic results has been repeatedly reported,2-3, 5-6 but there has been few report on the observation of long-term therapeutic effects after treatment. With acupuncture as the main therapy, 109 cases of knee osteoarthritis were treated in this series. 91 cases with good therapeutic results were followed up for 6 months. A report is presented in the following.展开更多
Elotuzumab was approved by the US FDA in 2015 as a new drug for the treatment of multiple myeloma（MM）, and it became a new choice for MM patients. The drug is the first immunostimulatory drug to treat MM and used to...Elotuzumab was approved by the US FDA in 2015 as a new drug for the treatment of multiple myeloma（MM）, and it became a new choice for MM patients. The drug is the first immunostimulatory drug to treat MM and used to treat recurrent/refractory multiple myeloma（R/RMM） in combination with lenalidomide and dexamethasone. Therefore, we collected the reports from existing clinical trials to analyze the efficacy of the drug in clinical applications to better evaluate the effects of the drug on R/RMM. The search strategy used ＂elotuzumab＂ and ＂multiple myeloma＂ as keywords to search from the database of Cochrane, Embase, Pub Med and Medline. The heterogeneity among the studies was assessed using the Cochrane χ~2 test, and its extent was evaluated using I^2 statistics. A P value of less than 0.05 was considered as statistically significant. All meta-analyses were conducted with R Software 3.3.2. We identified eight prospective studies consisting of 608 MM patients. The meta-analysis showed that the overall response rate（ORR） was 63%, 162 patients（26.6%） achieved a very good partial response rate（VGPR）, and 34 patients（5.59%） achieved complete response rate（CR）. The most common adverse effects of the drug included anemia, lymphopenia, thrombocytopenia, neutropenia and fatigue. Therefore, elotuzumab combination regimens offered clinical benefits to R/RMM patients, and such a combination therapy was a suitable option for continuous treatment for R/RMM patients.展开更多
文摘We present a rare case of primary chondrosarcoma of the liver in a 57-year-old man with pre-existing hepatitis B virus-related chronic hepatitis.The MRI scans showed a huge cystic-solid occupation of 18 cm×17 cm×11 cm in the right hepatic lobe.The tumor was completely resected,and the histological findings identified low-grade cartilaginous component with typical ring-and-arc chondroid matrix mineralization.Immunohistochemically,the neoplastic cells were positive for vimentin and S-100 protein.The patient received once postoperative adjuvant transcatheter arterial chemoembolization(TACE)at the 2nd month after discharge,and he is still alive for more than 13 months without recurrence and metastasis.To the best of our knowledge,this is the first case of primary chondrosarcoma of the liver.
文摘Summary Existence of a graft-versus-myeloma effect has been well documented by responses to donor lymphocyte infusions and long-term survival after allogeneic bone marrow transplantation. The development of non-myeloablative conditioning regimens allows utilization of allogeneic effects in patients usually not suitable for myeloablative allogeneic transplantation, such as older and heavily pretreated patients. In a small series of 11 patients with multiple myeloma relapsing after autologous transplantation, we show that conditioning with low-dose total body irradiation in combination with fludarabine allows stable engraftment after matched unrelated donor transplantation and is tolerated with acceptable transplant-related morbidity and mortality. With a short median follow-up of 225 days, disease control was achieved only for patients responding to conventional treatment prior to allografting. Future studies with longer follow-up have to define the role of non-myeloablative allogeneic transplantation from unrelated donors as consolidation for patients responding to salvage therapy.
文摘Knee Osteoarthritis, a retrograde disease, is mainly characterized by pain in the knee joints and limitation of the movement. It is a common and frequently occurring disease affecting the health and life quality of old people. In recent years, acupuncture treatment of knee osteoarthritis with satisfactory therapeutic results has been repeatedly reported,2-3, 5-6 but there has been few report on the observation of long-term therapeutic effects after treatment. With acupuncture as the main therapy, 109 cases of knee osteoarthritis were treated in this series. 91 cases with good therapeutic results were followed up for 6 months. A report is presented in the following.
基金Zhejiang Public Welfare Technology Application Research Project(Grant No.2015C33285)Zhejiang Provincial Natural Science Foundation Project(Grant No.LY14H300002)+1 种基金Shaoxing Science and Technology Bureau General Project(Grant No.2015B70070)Zhejiang Medical and Health General Research Program(Grant No.2013KYB030)
文摘Elotuzumab was approved by the US FDA in 2015 as a new drug for the treatment of multiple myeloma（MM）, and it became a new choice for MM patients. The drug is the first immunostimulatory drug to treat MM and used to treat recurrent/refractory multiple myeloma（R/RMM） in combination with lenalidomide and dexamethasone. Therefore, we collected the reports from existing clinical trials to analyze the efficacy of the drug in clinical applications to better evaluate the effects of the drug on R/RMM. The search strategy used ＂elotuzumab＂ and ＂multiple myeloma＂ as keywords to search from the database of Cochrane, Embase, Pub Med and Medline. The heterogeneity among the studies was assessed using the Cochrane χ~2 test, and its extent was evaluated using I^2 statistics. A P value of less than 0.05 was considered as statistically significant. All meta-analyses were conducted with R Software 3.3.2. We identified eight prospective studies consisting of 608 MM patients. The meta-analysis showed that the overall response rate（ORR） was 63%, 162 patients（26.6%） achieved a very good partial response rate（VGPR）, and 34 patients（5.59%） achieved complete response rate（CR）. The most common adverse effects of the drug included anemia, lymphopenia, thrombocytopenia, neutropenia and fatigue. Therefore, elotuzumab combination regimens offered clinical benefits to R/RMM patients, and such a combination therapy was a suitable option for continuous treatment for R/RMM patients.
